KR20160064993A - A pharmaceutical or food composition containing the fermentative products of houttuynia cordata converted biologically by Basidiomycota hyphae or lysate of Basidiomycota hyphae with anti-allergenic effect - Google Patents

Abstract

The present invention relates to a therapeutic pharmaceutical composition or food composition having antiallergic ability including a fermentation product of a biotransformed fermented product through fermentation of a microorganism (mycelium mycelium) and an enzyme treatment, wherein the biotransformation The fermented product of the fermented sea mustard contains a large amount of antiallergenic substance compared to the fermented fermented soybean, so that it is possible to reduce the incidence of allergies when it is developed into foods and the like.

Description

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a therapeutic pharmaceutical composition or food composition containing fermented microorganisms (mycelia of mycelia) or fermented by fermentation of biotransformed fermented seaweeds through further treatment with enzymes, or a food composition containing the fermentative products of houttuynia cordata converted biologically by Basidiomycota hyphae or lysate of Basidiomycota hyphae with anti-allergenic effect}

The present invention relates to a therapeutic pharmaceutical composition or food composition having an antiallergic ability comprising a fermented microorganism (mycelium mycelium) fermented or a biologically converted fermented product of a fermented soybean by an enzyme treatment.

Allergic diseases are so widespread that about 25% of all people suffer from one or two allergies. The prevalence of allergic rhinitis in developed countries has increased by 10% every year for the past 30 years. In recent years, the statistics of allergic patients in urban areas show that 15 ~ 20% of rhinitis. Asthma 6 ~ 8%, atopy 10 ~ 15%, eye allergy 3%, and the number of patients with at least one allergy is about 25%. It is estimated that allergic diseases have a very high socioeconomic cost. According to the Korea Asthma Association 2005 report, the socio-economic cost of bronchial asthma reaches 2 trillion won per year. The prevalence of allergic diseases in developed countries is higher than that of underdeveloped and developing countries, and the incidence of allergic diseases is expected to increase in Korea.

Common treatments for allergic diseases include avoidance, drug, surgery and immunotherapy. Avoidance is the most basic and important treatment method to avoid causative antigens. It is a very important method for the management of allergic diseases, but there is a difficulty in completely avoiding causative agents that cause immune reactions. Drug therapy has shown the greatest progress in the treatment of allergic diseases, but current drug therapy is a treatment that inhibits the secretion of chemical messengers. In addition, steroids, antihistamines, sympathomimetics, theophylline, etc. have been used in the selection of therapeutic agents for 20 years or more, with the exception of leukotriene modifiers. Although there is a growing concern about the importance of anti-inflammatory drugs such as steroids for persistent allergic diseases such as chronic asthma, this treatment strategy is not aimed at primary prevention or cure of allergic diseases. Operative therapy includes surgery for cirrhosis, cryosurgery, diathermy, neurosurgery, and laser ablation. However, since the pathology of allergic diseases is not corrected by surgery, , The symptoms often recur. Immunotherapy is a method to induce a change of immune response in the body by continuously and regularly administering the causative antigen when the antigen is revealed through various inspection methods, and as a method to reduce the susceptibility to the causative substance.

As described above, since most of the allergic diseases have no special therapeutic agent or preventative agent other than the symptomatic treatment, there is a need for development of raw materials and products for health functional foods derived from natural materials. Techniques such as the pharmaceutical compositions for treating allergic diseases (KR 2005-0079256 and KR 0991399), which include an extract of Aspergillus oryzae as an active ingredient, have been developed so far. However, microorganisms (mycelium mycelium) have been fermented, The development of technologies for the treatment and prevention of allergic diseases using fermented water as an active ingredient has not been developed yet.

Accordingly, the present invention relates to a therapeutic pharmaceutical composition or food composition containing an allergenic fermented product of fermentation of bacillus strains hyphae or further biologically converted through enzymatic treatment, and its effect.

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made keeping in mind the above problems occurring in the prior art, and an object of the present invention is to provide an antiallergic therapeutic pharmaceutical composition or food comprising fermented fish, ≪ / RTI > However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, for purposes of complete understanding of the present invention, various specific details are set forth, such as specific forms, compositions and processes, and the like. However, certain embodiments may be practiced without one or more of these specific details, or with other known methods and forms. In other instances, well-known processes and techniques of manufacture are not described in any detail, in order not to unnecessarily obscure the present invention. Reference throughout this specification to "one embodiment" or "embodiment" means that a particular feature, form, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Accordingly, the appearances of the phrase " in one embodiment "or" an embodiment "in various places throughout this specification are not necessarily indicative of the same embodiment of the present invention. In addition, a particular feature, form, composition, or characteristic may be combined in any suitable manner in one or more embodiments.

Unless defined otherwise in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

In one embodiment of the present invention, the basidiomycetes are fungi, which are cells of the fungus as a result of the sexual reproduction of the fungus as a result of the sexual reproduction. There are many things known as mushrooms which are parasitic to other organisms because they can not make their own nutrients. Typical examples are mushroom, mushroom, shiitake, mushroom, mushroom, and mushroom. On the freshly corrugated side of adult mushrooms, a lot of volcanic ash is formed. Most of the basidiomycetes mushrooms live in secondary life in the fluid of higher plants. In particular, they decompose cellulose and lignin to play an important role in the biological circulation of the material. In addition, they form mycorrhiza in the roots of trees, There are many. There are other kinds that are important as edible bacillus or should be cautious with poisoning.

In one embodiment of the present invention, mycelium is a nutritive cell of a filamentous fungus. Functional differentiation such as nutritional function or physiological function can also be seen. Morphologically, the presence or absence of the bulkhead is used for classification, and it develops in germination tube of spore and elongates by tip growth. The group of branched mycelium is called mycelium. Depending on the physiological function, it is distinguished into basal hypha that grows on the surface or inside of the pouch or host, and parasitic bacteria which grows in the air. Parasitoids depend on the transfer of nutrients from basal hyphae, some of which differentiate into spore forming organs and the like. If there are organic matter and suitable environmental conditions such as appropriate humidity and temperature, various mycelial tissues are formed. The mycelial membrane of mycelium of fungus is simple, but it can be seen that it forms a braid connection. In the fungi, it branches into several branches and is entangled like a thread. It does not have chlorophyll and does not have photosynthesis. It attaches to the host organism and absorbs nutrients. In the case of the mushroom-bearing bacterium, the mycelium germinated in the spore has one nucleus, which when fused with another mycelium has two nuclei in one cell. Mycelium with one nucleus is called mycelium, and mycelium with two nuclei is called secondary mycelium. The cell wall of the mycelium is generally composed of chitin or hemicellulose, which is sometimes combined.

In the present specification, the mycelia of mycelia can be selected from mycelium of mushroom, chaga mushroom, shiitake mushroom, mushroom mushroom, mushroom mushroom, The mycelia of these mycelia were collected from the KCCM, KCTC, KCLB, KACC, ATCC, And the like.

In one embodiment of the present invention, Houttuynia cordata Thunberg is a perennial plant of the dicotyledonous plant pepperyus saury. It grows in the shaded forests, the stems of the ground are long and thin and white. The stem is straight and 20-50cm high, with several vertical lines and smell. Leaves are alternate phyllotaxis, 3 ~ 8cm long, pointed end, plain edge, stipule attached to bottom of petiole. The flower blooms in May ~ June, ending at the end of the stem of the stem, forming numerous inflorescence. The involucre is divided into 4 pieces and ran under the inflorescence in a cruciform shape and looks like petal. The divided pieces are oval or long elliptical shape with a length of 1.5 ~ 2cm and white. The length of the inflorescences is 1 ~ 3cm, the flowers have no petals and calyxes, there are 3 stamens and 1 pistil, 3 styles, and the ovaries are upper and 3 chambers. The fruit is seed vessel, and the seed is light brown. Use the plants before the flowering as a diuretic and insect repellent, and apply the leaves when they are bitten by boils and insects. In the private sector, it is used for swelling, pneumonia and hemorrhoids. In one room, plants are used for gonorrhea, enteritis, urinary tract infections, pneumonia and bronchitis. Leaves are similar to the leaves of buckwheat and are called ammoil. It is distributed in Korea (Ulleungdo, Anmyeon, Geoje Island), Japan, China, Himalaya and Java.

In one embodiment of the present invention, bioconversion refers to the conversion of a substance added using a physiological function of an organism into a chemically modified form.

In one embodiment of the present invention, fermentation refers to a process in which a microorganism decomposes an organic substance using an enzyme contained therein. Fermentation is a phenomenon in which organic matter changes into a simple compound by enzymatic action and releases free energy. In general, microorganisms decompose organic matter and accumulate metabolites. That is, fermentation of alcohol by anaerobic digestion of sugars by anaerobic digestion of yeast, fermentation of lactic acid by lactic acid bacteria decomposing sugar nonoxiously into lactic acid is a typical fermentation, but now, A phenomenon in which alcohol is oxidized to acetic acid by use of oxygen, and a phenomenon in which mold oxidizes glucose to gluconic acid by using oxygen in the air are also referred to as acetic acid fermentation and gluconic acid fermentation. In addition, these anaerobic fermentation can be divided into anaerobic fermentation and aerobic fermentation (oxidation fermentation), and other anaerobic fermentation fermentations include glycerol fermentation, acetone butanol fermentation, 2, 3-butylene glycol fermentation, butyric acid fermentation, Fermentation, and methane fermentation. Examples of aerobic fermentation include citric acid fermentation, itaconic acid fermentation, yeast acid fermentation, 2-keto glutaric acid fermentation, oxalic acid fermentation, fumaric acid fermentation and sorbose fermentation. In addition, production of amino acids, vitamins and antibiotics by microorganisms is also called glutamic acid fermentation, riboflavin fermentation, penicillin fermentation and the like, which is not a good title. The name of the fermentation is usually called the product, but sometimes the name of the substrate is given by cellulosic fermentation, pectin fermentation and so on.

In one embodiment of the present invention, an allergic disease is a disease caused by allergies. Allergy refers to an antigen-antibody reaction that occurs when an IgE antibody is produced against a substance of interest (antigen or allergen), and then the same antigen enters the body. The major diseases are bronchial asthma, allergic rhinitis, urticaria, leukemia, drug allergy, seropositivity, and various types of diseases depending on the type of allergen or tissues causing allergic reactions. Diagnosis of allergic diseases refers to the progress of the family or patient until that time, the time of onset, the living environment, and the contents of the meal consumed. In some cases, it may be necessary to remove the suspicious allergen and observe the improvement of the symptoms, and to induce allergens. Other skin reactions include scratch tests or skin reactions. Therapeutic methods include elimination of allergens, desensitization therapy, and drug therapy to suppress allergic reactions. As a typical allergic disease of the respiratory system, allergic rhinitis shows hypersensitivity to the nasal mucosa of a specific substance. After the nasal mucosa is exposed to the causative substance (allergen), all parts of the nasal mucosa IgE antibody-mediated inflammatory cells are involved in inflammatory reactions caused by various mediators secreted by these cells. It is characterized by three main symptoms: continuous seizure sneezing, clear runny nose, and nasal congestion. Allergic rhinitis can be suspected when two or more of these three symptoms are present. In addition to the characteristic symptoms, it may be accompanied by symptoms such as itching around the nose, headache, loss of smell, and complications such as otitis media, sinusitis and pharyngitis.

In one embodiment of the invention, IgE is an antibody protein, also called immunoglobulin E. It is often called an "allergic antibody" because it plays an important role in allergic reactions. If you are allergic to certain substances (allergens), the immune system mistakenly thinks that harmful substances are harmful to your body. When you are exposed to this particular substance, the immune system begins to produce IgE to protect your body. IgE antibodies remain in the body and then come into contact with allergens again, causing allergic reactions. As a result, people with allergies have elevated serum IgE levels, and IgE has specificity for each allergen.

In one embodiment of the present invention, histamine is a substance produced by the action of histidine decarboxylase, which is an amino acid, histidine. It is mainly stored in mast cells and is released when the cells are damaged due to wound, bacterial infection, Histamine released plays an important role in immune function by expanding the blood vessels and increasing the permeability of the blood vessels, allowing white blood cells and various plasma proteins to move quickly to the site where the bacteria have entered. The excessive secretion of histamine due to excessive immune responses may cause allergic reactions and anaphylaxis. Besides these immune functions, it is one of powerful active agents that regulate the movement of the uterus during pregnancy and secrete gastric juice. It also causes an increase in blood flow due to vasodilation.

In an embodiment of the present invention, the pathogenesis of allergy is described in detail. Allergy refers to a symptom in which an exaggerated immune response to an exogenous substance is exerted. The allergic disease is mainly caused by a Th2 cell mediated immune response Lt; / RTI > Acute and mild allergic diseases such as seasonal allergic rhinitis are characterized by increased allergen-specific IgE antibodies, IgE-dependent activation of mast cells, and invasion of activated Th2 cells and eosinophils into the mucosal surface.

In relation to the onset of allergy, ① allergen-inducing antigen enters our body to activate antigen-specific Th2 cells, ② cytokine secreted by activated Th2 cells (IL-4, etc.) When class switching occurs and IgE antibody production is induced and secreted, our body becomes sensitive to allergens. At this time, when the allergen is reintroduced, the IgE antibody mediated reaction occurs and allergic symptoms appear. That is, when the IgE antibody binds to the IgE receptor of the mast cell and the mast cell is sensitized, the mast cell is activated when the allergic antigen is re-introduced to the mast cell surface, and the degranulation is immediately induced and the intracellular granule such as histamine And inflammatory cytokines, are secreted out of the cell. Allergic reactions are triggered by several chemical allergen mediators secreted. Allergic reactions can be divided into early reaction and late reaction. The initial reaction occurs within a few minutes and secretes mediators of already-produced mediators such as histamine, β-hexosaminidase, and serotonin and newly synthesized lipid components from mast cells And the late response occurs within a few hours. IL-4, IL-5, and IL-13, which are typical cytokines of Th2 immune response, are synthesized and secreted to continue the inflammation reaction. Mediators and cytokines of lipid components, newly produced by mast cells, are the major factors causing allergic acute and chronic inflammatory responses. (4) Eosinophil infiltration and induction of eosinophils in peripheral tissues by cytokines (IL-5, etc.) secreted from cells and mast cells induces eosinophil hyperplasia, which is called eosinophilic allergy. In addition, IL-13 induced hypersensitivity by inducing hypersensitivity. Eosinophilia is a direct cause of induction of allergic hypersensitivity reaction.

In the case of an allergic disease caused by an excessive immune response, it is necessary to control the aggressive immune response. Inhibition of the Th2 immune response by inducing the Th1 immune response and the Treg immune response, (IL-4, IL-5, and IL-13), (3) reduce eosinophils and mast cells in allergic inflammation sites, and Immunomodulating treatments such as reducing hypersensitivity suggest new possibilities for the treatment of allergic diseases.

In one embodiment of the present invention, sepsis refers to a condition in which a microorganism is infected and a serious inflammatory reaction occurs in the whole body. The number of breaths increased more than 24 times per minute (ventilation), heart rate more than 90 times per minute (tachycardia), increase in leukocyte count in blood test, or significant decrease in respiratory rate If you have symptoms that are more than a branch, it is called systemic inflammatory response syndrome (SIRS). This systemic inflammatory response syndrome is called sepsis when it is caused by microbial infection. The source of the infection can be any organs of the body. Pneumonia, pyelonephritis, meningitis, cellulitis, infective endocarditis, peritonitis, pressure ulcer, cholecystitis, and cholangitis may cause sepsis. If such infection occurs, the causative microorganism may invade into the blood and cause sepsis. However, even if microorganisms do not penetrate into the blood, systemic sepsis may occur due to the inflammation reaction of some body parts and the production of inflammatory substances. Early symptoms of sepsis may include respiratory arrest, neurological disturbances such as loss of locomotion (time, place, cognitive ability) or delirium. The skin may appear visually opaque due to lowering of blood pressure and lowering of the amount of blood supplied to the distal end of the body. Bacteremia (a symptom of germs circulating in the blood) can cause germs to move around the bloodstream, to position themselves in certain parts of the body and cause pathological changes in those areas. As the skin changes specific to the causative bacteria, it may help to diagnose the cause of sepsis. Symptoms of the digestive system include nausea, vomiting, diarrhea and intestinal paralysis, and severe gastrointestinal bleeding may also occur.

In one embodiment of the present invention, the pharmaceutical composition means a composition to be administered for a specific purpose. For the purpose of the present invention, the pharmaceutical composition of the present invention is used for enhancing the survival rate or inhibiting the inflammatory active substance in the sepsis-induced group, and comprises a composition for this purpose and a pharmaceutically acceptable carrier, excipient or diluent . The pharmaceutical composition according to the present invention comprises 0.1 to 100% by weight of the active ingredient corresponding to the pharmaceutical composition of the present invention, based on the total weight of the composition. Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In one embodiment of the present invention, the food composition is variously used as a food composition for improving allergic diseases. The food composition containing the composition of the present invention as an active ingredient may be used in various foods such as beverages, Tea, vitamin complex, powder, granule, tablet, capsule, confection, rice cakes, bread and the like. Since the food composition of the present invention is composed of a natural food and its fermented product which have little toxicity and side effects, it can be safely used for prolonged use even for prophylactic purposes. When the composition of the present invention is contained in the food composition, the amount thereof may be added in a proportion of 0.1 to 100% of the total weight. Here, when the food composition is prepared in a beverage form, there are no particular limitations other than those containing the food composition at the indicated ratios and may contain various flavors or natural carbohydrates such as ordinary beverages as an additional ingredient. That is, natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, sucrose and the like, and sugar sugars such as polysaccharide, dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol can do. Examples of the flavors include natural flavors (such as tau martin, stevia extract (for example, rebaudioside A and glycyrrhizin), and synthetic flavors (for example, saccharin and aspartame). The food composition of the present invention can be used as a food composition containing various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and its salts, alginic acid and its salts, Stabilizers, antiseptics, glycerin, alcohols, carbonating agents used in carbonated beverages, etc. These components may be used independently or in combination. The ratio of these additives is not so important, Is generally selected in the range of 0.1 to about 100 parts by weight per part.

In one embodiment of the present invention, the cosmetic composition is a composition for improving an allergic skin condition or an allergic skin disease. The cosmetic composition comprising the composition of the present invention as an active ingredient can be used as a skin lotion, a nutritional lotion, a nutrition essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, Skin lotions, skin creams, sunscreen cosmetics, cleansing milks, hair removal products, cosmetics, face and body lotions, face and body creams, skin whitening creams, hand lotions, hair lotions, (Non-medical use), cream soap, facial wash, hair rinse, make-up soap, tooth whitening gel, toothpaste, etc. . ≪ / RTI > To this end, the compositions of the present invention may further comprise suitable carriers, excipients or diluents conventionally used in the preparation of cosmetic compositions. The carrier, excipient or diluent which may further be added to the cosmetic composition of the present invention include purified water, oil, wax, fatty acid, fatty acid alcohol, fatty acid ester, surfactant, humectant, thickener, antioxidant, Buffers, lower alcohols, and the like, but are not limited thereto. Further, if necessary, it may contain a whitening agent, a moisturizing agent, a vitamin, an ultraviolet screening agent, a perfume, a dye, an antibiotic, an antibacterial agent, and an antifungal agent. As the oil, hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil and avocado oil may be used. Examples of the wax include wax, wax, carnauba, candelilla, montan, ceresin, liquid paraffin, Can be used. Examples of the fatty acid include stearic acid, linoleic acid, linolenic acid and oleic acid. The fatty acid alcohols include cetyl alcohol, octyldodecanol, oleyl alcohol, panthenol, lanolin alcohol, stearyl alcohol and hexadecanol As the fatty acid ester, isopropyl myristate, isopropyl palmitate, and butyl stearate may be used. As the surfactant, a cationic surfactant, an anionic surfactant and a nonionic surfactant known in the art can be used, and a surfactant derived from a natural material is preferably used. In addition, it may contain a hygroscopic agent, a thickening agent, an antioxidant and the like widely known in the field of cosmetics, and the kind and amount thereof are well known in the art.

In one embodiment of the present invention, there is provided a method for producing a microorganism, comprising the steps of: (a) cultivating a perennial herb as a liquid medium; (b) bioconverting fermentation in which the microbial mycelium is inoculated into a culture medium- And (c) producing a biotransformation product of the fermentation and enzyme treatment which has improved antiallergic efficacy from the fermentation product produced by the biotransformation fermentation process of the step (b) through the biotransformation enzyme treatment process The method for producing a fermented product having increased antiallergic activity, comprising the steps of: (a) cultivating the herringbone in a culture medium, the herringbone powder powdered with the herringbone powder is treated with a hydrolytic enzyme, Wherein the enzymatic treatment is a treatment of a cellulolytic enzyme capable of degrading a cell wall component and an enzyme of an amylase family Characterized in that the fibrinolytic enzyme is selected from the group consisting of cellulase, hemi-cellulase, pectinase and glucanase, which has an antiallergic efficacy increased fermented product Wherein the mycelia of mycelia of step (b) are selected from the group consisting of mycelia of mycelia selected from the group consisting of mushroom, mushroom, mushroom, mushroom, mushroom, mushroom, Wherein the biotransformation product of step (c) inhibits the secretion of IgE in B cells that secrete IgE, and also inhibits the secretion of histamine in mast cells. Wherein the biotransformation product of step (c) is selected from the group consisting of TNF-a, IL-6, IL-10 and IFN- wherein the biological conversion product of step (c) is selected from the group consisting of serum TNF-α, IL-1β and oxidized serum, which are indicators of systemic inflammation in sepsis syndrome, in a fermented product having increased antiallergic activity, The present invention also provides a method for producing fermentation products having increased anti-inflammatory effects which reduce the concentration of nitrogen.

In another embodiment of the present invention, there is provided a fermented product having increased antiallergic activity, which is fermented by fermenting culture inoculated with a mycelium of Mycobacterium strains, and provides the fermented product with increased antiallergic potency, wherein the allergic rhinitis is allergic rhinitis, Antiallergic efficacy reduces the production of IL-2, IL-10, IL-12, and gamma-interferon, as well as reducing IgE production in allergic symptoms and inhibiting the production of IL-4, IL-5 and IL- In a fermented product having increased antiallergic activity.

In another embodiment of the present invention, there is provided a pharmaceutical composition for the treatment of allergy comprising fermented product having increased antiallergic potency, which is fermented by culture inoculated with a mycelium of Mycelia, and wherein the allergen is an allergic rhinitis Lt; / RTI >

In another embodiment of the present invention, there is provided a pharmaceutical composition for the treatment of inflammation comprising fermented product having increased antiallergic potency, which is cultured fermented by inoculating mycelia with mycelia, wherein the inflammation treatment is a treatment for inflammation To provide a pharmaceutical composition.

In another embodiment of the present invention, there is provided a food composition for anti-allergy comprising a fermented product having increased antiallergic potency obtained by inoculating mycelia with a mycelium of Mycobacterium sp.

In another embodiment of the present invention, there is provided a cosmetic composition for antiallergic comprising a fermented product having increased antiallergic potency, which is fermented by culture inoculated with a mycelium of Mycobacterium tuberculosis.

Hereinafter, the present invention will be described in detail.

Fermented product of fermented microorganisms (mycelium mycelium) or biologically converted by further treatment with enzymes contains a large amount of antiallergenic substance compared to unfermented fermented soybean extract It is anticipated that there will be an effect of reducing the occurrence of allergy.

FIG. 1 is a schematic view showing a cultivation medium of an elm, a bioconversion process, and a fermentation powder obtained according to an embodiment of the present invention.
FIG. 2 is a graph showing the activity of inhibiting the production of IgE antibodies according to the concentration of raw material and fermented product according to one embodiment of the present invention.
FIG. 3 is a graph showing the results of inhibiting activity of mast cell degranulation according to concentration of raw material and fermented product according to one embodiment of the present invention.
FIG. 4 is a graph showing histamine release inhibitory activity according to the concentration of the raw material and fermented product according to an embodiment of the present invention.
FIG. 5 is a graph showing the results of measurement of cytotoxicity according to the concentration of the raw material and the fermented product, according to an embodiment of the present invention.
FIG. 6 is a graph showing the results of evaluation of the ability of TNF-.alpha. To be expressed according to the concentration of the raw material and fermented product according to an embodiment of the present invention.
FIG. 7 is a graph showing the results of evaluating the IL-6 expression-producing ability according to the concentration of the raw material and the fermented product according to an embodiment of the present invention.
FIG. 8 is a graph showing the results of evaluating the IL-10 expression-producing ability according to the concentration of the raw material for fermentation and the fermentation product according to an embodiment of the present invention.
FIG. 9 is a graph showing the results of IFN-.beta. Expression assay according to the concentration of the raw material and the fermented product according to an embodiment of the present invention.
10 is a diagram illustrating a method of producing an experimental animal model of OVA-sensitization (allergic rhinitis / asthma) mouse according to an embodiment of the present invention.
11 is a graph showing the results of measurement of IgE concentration in BALF and blood of an OVA-sensitized animal model according to an embodiment of the present invention.
FIG. 12 is a graph showing the results of measurement of concentrations of representative Th1, Th2 and Treg immunoreactive cytokines in bronchoalveolar lavage fluid (BALF) of an OVA-sensitized animal model according to an embodiment of the present invention.
FIG. 13 is a graph showing the results of measurement of concentrations of representative Th1, Th2, and Treg immunoreactive cytokines in the blood of an OVA-sensitized animal model according to an embodiment of the present invention.
FIG. 14 is a graph showing the results of confirming the effect of BALF on the number of immune cells such as eosinophils in an OVA-sensitized animal model according to an embodiment of the present invention. FIG.
FIG. 15 is a graph showing changes in mortality according to concentration and route of administration of fermented sea mustard in a sepsis-induced animal model according to an embodiment of the present invention. FIG.

Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example  1. Bioconversion process of fermentation and enzyme treatment

Example  1-1. Pretreatment

For the pretreatment process from the raw material to the pulverized raw material, the fungal contamination degree of the raw material was measured, and then water washing work was performed to remove foreign matters and contaminants from the natural raw material. (1) air washing step to remove foreign matters and mold spores, (2) water washing step to remove residual pesticides, (3) alcohol (Et-OH) to remove contaminants such as microorganisms, Washing of the raw materials was carried out through the washing step. After washing and cutting, the raw materials were dried in a hot air drier capable of mass drying, and subjected to pulverization of each of the natural raw materials through crude pulverization and pulverization.

Example  1-2. Obtain Fermented Powder of Hwasungcho

The foreign matter and fungal contamination were removed by enzymatic treatment and heat treatment sterilization for liquid culture medium. The enzymes are hydrolyzed by cellulosic and hemi-cellulosic hydrolytic enzymes capable of decomposing bark, muscle, root, and leaf, and hydrolytic enzymes such as pectinase, glucosidase and amylase hydrolytic enzymes , And the enzyme was added, followed by reaction at 60 ° C for 1 hour, followed by sterilization at a high temperature for 30 minutes to cultivate the herringbone.

Then, the mycelium of mycelia cultivated separately in the culture (fermentation) medium was added. When the concentration of the residual carbon source is depleted to a certain concentration or less under the condition of inoculating 10% (v / v) culture of mycelium mycelium culture at 28 ~ 30 ° C and pH 4.5 ~ 7, And cultured for 7 to 10 days in a food process. The above mycelium of mycelia may be selected from mycelia such as mushroom, chaga mushroom, shiitake mushroom, mushroom mushroom, mushroom mushroom, snow mushroom mushroom, and skirting mushroom, which are medicinal and edible bacillus species, Ryu Myung-sa is a member of the Korean Society for Microbiology (KCCM), Korea Biotechnology Research Institute (KCTC), Korea Cell Line Bank (KCLB), Korea Agricultural Microbiology Resource Center (KACC) It is possible to use the strain in an institution.

The enzymatic treatment of the biotransformation process for the above fermented product is carried out by adding various enzymes such as cellulose decomposing enzyme, cellulase, hemicellulase, pectinase and glucanase after hot water extraction to an appropriate amount (The optimum amount indicated in the product manual of each enzyme preparation). Examples of the enzymes include commercially available enzymes such as a cellulase (a compound derived from Aspergillus niger), a filtrate (a compound derived from Filtrase (Tricoderma reesei)), a rapidase (a compound derived from a fibrinolytic enzyme, Viscozyme (Complex containing Aspergillus niger) and Sumizyme (a complex containing Aspergillus niger-derived pectinase) was added at the recommended concentration (10% v / v) given in the product manual of each enzyme preparation, The enzyme / substrate reaction was performed by rotating at 250 rpm for 1 to 3 hours.

The fermented product of the fermented seaweed produced by the biotransformation process was inactivated and sterilized at 90 ℃ for 1 hour and then lyophilized and powdered. In addition, the above-mentioned fermentation product of yeast fermented with immunostimulatory activity was dissolved in 10 times of water and centrifuged at 10,000 rpm for 30 minutes to remove insoluble residues. The supernatant was lyophilized to obtain a water-soluble powder or 5-fold ethanol Followed by induction of precipitation at 4 DEG C for 24 hours or longer, and the precipitate was lyophilized to obtain a powder of a polymeric polysaccharide fraction having immunological activity. The culture broth culture, bioconversion process and fermentation powder production process of the above-mentioned Hwasungcho are shown in Fig.

Example  2. Biotransduced  Sophora Fermented  Evaluation of in vitro efficacy

Example  2-1. In B cells IgE  Evaluation of Antibody Production Inhibitory Activity

Biotransformation was Houttuynia cordata were purchased the U266B1 cell line (B cells of human origin) for identifying a fermented water IgE production suppressing effect on the global cell bank (ATCC), 15% to 37 ℃, conditions of 5% CO _2, saturated humidity The cells were cultured in RPMI-1640 medium supplemented with heat-inactivated fetal bovine serum (FBS) and 100 units of penicillin and 100 μg / ml of streptomycin. After inoculation the U266B1 cells to 1 x 10 ⁶ cells / well density in a 96 well culture plate and cultured overnight. After incubation, B cells were stimulated by treatment with 10 μg / ml of LPS and 5 ng / ml of IL-4. In addition to the stimulation, the raw material and the fermented material were treated at a concentration of 1, 10, and 100 μg / ml, respectively, for 72 hours. After incubation, the supernatant was collected and the amount of IgE secreted from U266B1 cells was measured using a Sandwich ELISA Assay (BETHYL, Montgomery, TX) kit. It was purchased and used in seven areas of Gyeongsangbuk-do, Gyeongbuk (DP), Busan (DP), Gangwon-do (GW), Gyeongsangbuk-do Yeongcheon (SD), Daegu (MS), Jeollanam-do Namwon (DM) All of the 7 strains were found to have an increased IgE antibody production inhibitory activity in a concentration - dependent manner. The highest inhibitory activity of GW (GW) acidophilus was obtained at 100 ㎍ / ㎖ concentration and the highest inhibitory activity was in 70% at 100 ㎍ / ㎖ of Gangwon - Max inhibitory activity. However, even in the case of MS, the inhibitory activity of both the raw material and the fermented product showed 24.5% and 61.5% inhibitory activity, respectively, and there was no significant difference from that of Gangwon (GW) The difference between the regions was not large. In addition, the inhibitory activity of IgE production was significantly increased in the case of fermented product compared with the raw material of all strains according to the place of origin. Notably, inhibition of IgE antibody production at a concentration of 1 ㎍ / ㎖ of fermented product at a concentration of 100 ㎍ / Activity is higher. The results are shown in Fig.

Example  2-2. In mast cells Degranulation  Evaluation of inhibitory activity

Beta-hexyl sosami is a kinase (β-hexosaminidase) inhibition were obtained for (mast cells of rat origin) RBL-2H3 cell line for the activity evaluation at the ATCC, 37 ℃, 5% CO 2, 10% under the conditions of saturation humidity complement Were cultured in DMEM medium containing inactivated FBS (heat-inactivated fetal bovine serum), 100 units of penicillin, and 100 占 퐂 / ml streptomycin. This was dispensed into a 96-well culture dish at 1 × 10 ⁵ cells / well and further cultured overnight. After incubation, the medium was removed and the cells were washed with thyloid buffer (137 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl ₂ , 1.1 mM MgCl ₂ , 11.9 mM NaHCO ₃ , 0.4 mM NaH ₂ PO ₄ , 5.6 mM glucose, pH 7.2), treated with the appropriate concentration of the material, and incubated at 37 ° C for 20 minutes. After three washes with thyloid buffer, 10 μM of A23187 (calcium ionophore) was treated and cultured for 20 minutes to induce degranulation. In the case of inducing degranulation using DNP-BSA, cells were inoculated with 1 ㎍ / ㎖ of IgE, sensitized, and treated with 100 ㎍ / ㎖ of DNP-BSA for 30 min at the appropriate concentration. Respectively. After induction, 100 μl of the supernatant was recovered, and 1 mM p-Nitrophenyl-β-Acetyl-Glucosamide 100 dissolved in 0.1 M citrate buffer (pH 5.0) The reaction was terminated by adding 200 μl of sodium bicarbonate buffer (pH 10.2) in a 37 ° C incubator for 1 hour. The reaction was terminated by using a microplate reader (Bio-Rad, Hercules, CA) The absorbance at 405 nm was measured.

In the beta - hexosaminidase assay, a comparative experiment was conducted on the raw materials and fermented products according to the place of origin. As a result, the inhibitory activity of each raw material and the fermented product was higher in the fermented product than in the fermented product There was no difference. When stimulated with A23187, Gangwon (GW) acid, which showed 54.5% and 58.9% inhibitory activity at 100 ㎍ / ml concentration, showed the highest inhibitory activity. In addition, it did not show a big difference from other native strains.

In the case of stimulation with DNP-BSA, the inhibitory activity of GW (GW) acid, which showed 42.7% inhibitory activity and 47.8% inhibitory activity, was found to be the most inhibitory activity at 100 μg / ml concentration, . In addition, the activity difference between the raw material and the fermented product did not appear to be significant, and it was found that the increase in the activity of inhibiting beta - hexosaminidase release by fermentation / enzyme - bioconversion was not significantly affected. The results are shown in Fig.

Example  2-3. Assessment of histamine inhibitory activity in mast cells

RBL-2H3 cell line (rat origin mast cells) for histamine evaluation was purchased from ATCC and incubated with 10% complement-inactivated fetal bovine serum (FBS) at 37 ° C, 5% CO2, And 100 units of penicillin and 100 [mu] g / ml streptomycin. After the cells were sensitized with A23187, the Gangwon-do (GW) acid weevil and fermented product were treated at 1, 10, and 100 ㎍ / ㎖ concentrations. To measure histamine, cultured RBL-2H3 cells were treated with 0.25% trypsin and the cells were harvested and suspended in thyloid buffer (137 mM NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1.1 mM MgCl2, 11.9 mM NaHCO3, 0.4 mM NaH2PO4, 5.6 mM glucose, pH 7.2) at a concentration of 1 × 10 ⁶ cells / well, and then dispensed into a 24-well culture dish. Subsequently, the cells were treated with an appropriate concentration of material and incubated for 15 minutes. Then, 10 μM of A23187 knife? The cells were treated with calcium ionophore and cultured again for 20 minutes. After culturing, the reaction was terminated by treatment at 4 ° C for 10 minutes, and the supernatant was recovered. To 1 ml of the recovered supernatant was added 0.2 ml of 1 N NaOH and 0.1 ml of 1% OPT (o-phthalaldehyde), and the mixture was allowed to stand at room temperature for 5 minutes. The reaction was terminated by treatment with 0.2 ml of 1 N HCl and then measured using a fluorescence meter (Molecular Devices, Sunnyvale, Calif.) At excitation wavelength of 360 nm and emission wavelength of 450 nm.

As a result of measuring the inhibitory activity of histamine release by using the raw materials and fermented products of Gangwon (GW), it was confirmed that 47.5% inhibitory activity was obtained in the raw material and 51.8% in the bioconversion fermentation product when treated at the concentration of 100 ㎍ / ㎖ , And the biosynthesis process of fermentation / enzyme treatment did not significantly affect the increase of histamine release inhibitory activity. The results are shown in Fig.

Example  2-4. Cytotoxicity Assessment

The RBL-2H3 cell line cultured by the method of Example 2-2 was dispensed into a 96-well culture dish at a concentration of 1 x 10 ⁴ cells / well, and then the weevils and the fermented product were cultured at a concentration of 1, 10, and 100 μg / And cultured for 48 hours. After the incubation, the supernatant was removed and 200 μl of a 0.5 mg / ml MTT reagent (3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) diluted in the medium was treated and cultured again for 3 hours Respectively. After incubation, the supernatant was removed and 200 μl of DMSO was added to dissolve the intracellular precipitate. The absorbance at 570 nm was measured using a microplate reader (Bio-Rad, Hercules, Calif.).

The results of cytotoxicity measurement of Gangwon (GW) acidophore in RBL-2H3 mast cell line showed no specific cytotoxicity and induction of proliferation at 100 ㎍ / ㎖ of both raw material and fermented product. The results are shown in Fig.

Example  2-5. In macrophages TNF Immune response using the expression rate of Activation ability  evaluation

In order to evaluate the activation of congenital immune responses of elm fermented products, culture and assay analysis of macrophages (macrophages) were carried out using 5% DMEM medium. The macrophages (macrophages) used for the immunoactivity measurement were RAW 264.7 cells, and the subcultures were subcultured in 0.5 ml each at a concentration of 1 × 10 ⁵ cells / ml in each well of a 24-well culture dish. After culturing for 24 hours, the cell culture was confirmed with a microscope, and the medium was completely removed and then washed 2-3 times with the medium without serum. Each well was filled with 0.5 ml of 5% FBS DMEM medium supplemented with a sample. The concentration of the sample was 1/10, starting at a concentration of 100 μg / ml, and adjusted to 1, 10, and 100 μg / Respectively. In addition, LPS in a final concentration of 1 / / ml was treated with a positive control (200 / / ml stock). 24 wells treated with the sample were incubated for 8-24 hours, and 400 μl of the culture solution of each well was taken. 400 μl of the culture solution was centrifuged at 12,000 rpm for 5 minutes, and the supernatant was used for assay analysis.

The expression of TNF-α was investigated in macrophages to confirm the innate immune response activation activity of the raw material and fermented product. Experiments were conducted by treating the raw material and fermented product at a concentration of 10 and 100 μg / ml. The culture supernatant, which had been treated for 18 hours after the sample was treated, was analyzed with an assay of TNF-α (R & D system, MTA00B) according to the manufacturer's protocol.

As a result, it was confirmed that TNF- The results are shown in Fig.

Example  2-6. Immune response using the expression rate of IL-6 in macrophages Activation ability  evaluation

The expression of IL-6 was examined in macrophages cultured in the same manner as in Example 2-4 in order to confirm the innate immune response activation effect of the raw material and fermented product. Experiments were conducted by treating the raw material and fermented product at a concentration of 10 and 100 μg / ml. The culture supernatant, which had been treated for 18 hours after the sample was treated, was analyzed with an assay of IL-6 (R & D system, M6000B) according to the manufacturer's protocol.

As a result, the expression of IL-6 was significantly increased in the group treated with the perennial fermentation product although the group treated with the perennial plant showed almost no expression of IL-6. The results are shown in Fig.

Example  2-7. Immune response using the expression rate of IL-10 in macrophages Activation ability  evaluation

The expression of IL-10 was examined in macrophages cultured in the same manner as in Example 2-4 in order to confirm the innate immune response activation effect of the raw material and fermented product. Experiments were conducted by treating the raw material and fermented product at a concentration of 10 and 100 μg / ml. The culture supernatant, which was treated for 18 hours after the sample was treated, was analyzed by IL-10 (R & D system, M1000) assay according to the manufacturer's protocol.

As a result, it was confirmed that IL-10 expression was higher in the fermented sea mustard. The results are shown in Fig.

Example  2-8. In macrophages IFN Immune response using the expression rate of? Activation ability  evaluation

The expression of IFN-β was examined in macrophages cultured in the same manner as in Example 2-4 in order to confirm the innate immune response activation activity of the raw material and fermented product. Experiments were conducted by treating the raw material and fermented product at a concentration of 10 and 100 μg / ml. The culture supernatant, which had been treated for 18 hours after the sample treatment, was taken and assayed according to the protocol of the manufacturer using an IFN-β (R & D system, 42400) assay.

The results showed that IFN-β expression was higher in the fermented sea mustard than in the whale raw material. The results are shown in Fig.

IFN-β is a cytokine that induces a Th1 immune response and is an immunomodulatory cytokine that inhibits the Th1 and Th17 immune responses while inducing a Th1 immune response. Allergy is known to occur as the Th2 immune response increases. It is expected that the fermented product of Hwasungcho may inhibit the expression of cytokine associated with the Th2 immune response which induces allergy by promoting the expression of INF-β associated with the Th1 immune response.

Example  3. Allergic rhinitis  In the model, Fermented  In the body (in vivo ) Efficacy evaluation

Example  3-1. Allergic rhinitis  Establishment of induction experimental animal model

In order to evaluate the antiallergic activity of the developmental material of the fermented product of the perennial plant, an experimental animal model of OVA-sensitization (allergic rhinitis / asthma) mouse was established. Egg white albumin (ovalbumin) was used as an antigen and alumina was used as a reinforcement agent. On the first day of experiment and 14 days, albumin albumin / alumina was sensitized by two intraperitoneal injections. After 2 weeks of elapsed time, allergic reaction was induced by inhalation of albumin albumin for 30 days for 30 days from 30 days. The evaluation of the fermented product was carried out by two ovalbumin / alumina peritoneal injections at the beginning and at the 14th day of the experiment, and then the oral administration was carried out at a dose of 10 ㎎ / ㎏ of the fermented product per day from the 15th day until the end of the experiment, . FIG. 10 shows the production method of the OVA-sensitized (allergic rhinitis / asthmatic) mouse experimental animal model.

Example  3-2. BALF  And blood IgE  produce Control ability  evaluation

As shown in FIG. 9, OVA-sensitized (allergic rhinitis / asthma) experimental animal model produced by the method of Example 3-1 induces an allergic reaction by inhalation of albumin albumin daily for 5 days from the 30th day of animal model production. In addition, the fermented seedlings were daily administered from the 15th day to the end of the experiment after sensitization with two albumin / alumina abdominal injections on the day of the experiment and on the 14th day, and mice were sacrificed on the 35th day, (BALF) were recovered and blood was also collected. The amount of immunoglobulin E (IgE) in the recovered BALF was 40.7% and 77.4%, respectively, indicating that the IgE production inhibitory activity was significantly increased. Immunoglobulin E in the blood was also inhibited by 21.9% in the perennial plant and 67.1% in the fermented plant. The results are shown in Fig.

Example  3-3. At BALF  Cytokine generation Control ability  evaluation

In order to investigate the degree of activation of Th2 cells that regulate the proliferation and activity of B cells, OVA-sensitization (allergic rhinitis / asthma) IL-5, and IL-13 in the group fed with the fermented product of the perennial herb, respectively, as a result of measurement of the amount of representative cytokines of the Th1 and Treg immunoreactions together with representative cytokines (OVA only) as compared with the control group (OVA only) and the control group (OVA only). On the other hand, the production of IL-10, a representative cytokine of Treg immunoreactivity with IL-2 and IL-12, which are typical cytokines of Th1 immune response, , And the intake of raw materials was also higher than that of the control group. The results are shown in Fig.

Example  3-4. Evaluation of cytokine concentration in blood

The concentrations of representative cytokines of Th1, Th2 and Treg immunoreactivity in the serum of OVA-sensitized (allergic rhinitis / asthma) experimental animal models were measured using the ELISA method as in Example 3-3. As a result, the production of IL-10, which is a representative cytokine of Treg immunoreaction, together with IL-2 and IL-12, which are typical cytokines of Th1 immune response, And the intake of raw materials was also increased compared with that of the control group. Gamma interferon (Interferon-γ or IFN-γ), which has been shown to inhibit eosinophil infiltration in allergic inflammation sites, is a typical cytokine secreted by Th1 cells. As compared with the control group and the ingestion group, , And the intake of raw materials was also higher than that of the control group. On the other hand, the production of IL-4, IL-5 and IL-13, which are representative cytokines of Th2 immune response, was decreased in the group fed with fermented fish fermented product compared to the control group (OVA only) And the intake of raw materials was also decreased compared to the control group. The results are shown in Fig.

Example  3-5. At BALF  Eosinophilia inhibition and On cell number  Check the effect

(BALF) of experimental animal model of OVA-sensitization (allergic rhinitis / asthma) due to the administration of fermented product of Hwasungcho was confirmed to inhibit eosinophilia and the effect on cell number. The results showed that the number of immune cells in the BALF was significantly decreased in the group fed with the fermented fish, compared with the group consumed with the raw material. In particular, the number of cells in eosinophils and lymphocytes was significantly reduced. The results are shown in Fig.

Example  In the sepsis model, Fermented  In the body (in vivo ) Safety evaluation

Example  4-1. Establishment of an animal model for induction of sepsis

Based on the in vivo safety evaluation results of fermented fermented fish, the limit dose and route of administration of fermented fermented fish were evaluated in vivo. LPS (20 ㎍ / kg) and galactosamine (700 mg / kg) were administered intraperitoneally for 2 weeks at a concentration of 1, 10 and 100 mg / Lt; / RTI >

Example  4-2. Comparison of lethal dose by concentration and route of administration

As a result of examining the mortality rate of mice up to 60 hours after the induction of sepsis in the experimental animal model according to the method of Example 4-1, 1 mouse and 10 mice in the experimental group administered with 1 mg / kg of the perch fermented fish in 10 mice per experimental group In the experimental group administered with 4 mg / kg / kg ip, 5 mice were observed to survive in the group administered with 100 mg / kg ip. In addition, at the dose of 10 mg / kg, , And 4 and 2, respectively, survived. That is, as the dose was increased to 1, 10, and 100 mg / kg, the survival rate was improved and it was confirmed that the fermented fish was a very safe immune modulating material, and it was confirmed to be a very effective substance in oral administration. The results are shown in Fig.

Example  4-3. Systemic inflammatory response  Indicators( TNF -α, IL- 1β , Nitric oxide) evaluation

As shown in Example 4-2, the mortality rate of sepsis at the LPS lethal dose was decreased due to the administration of the fermented fish juice fermented product, so that the inflammation inhibitory effect of the developmental material in the systemic inflammatory reaction was examined. (10 μg / kg) was administered orally for 2 weeks, followed by sub-lethal dose of LPS (5 μg / kg) and galactosamine (700 μg / kg) according to the determined dosage and administration route. mg / kg) to induce the systemic inflammatory response. After induction of inflammation for 4 hours, mice were sacrificed and blood was drawn from the heart. Serum was separated and the concentration of TNF-α, IL-1β and nitric oxide in the serum of the systemic inflammatory response was confirmed.

As a result of the experiment, it was confirmed that the mouse treated with the fermented product of Hwasungcho inhibited the production of TNF-α by 40% or more as compared with the control. IL-1β, which is a representative inflammatory cytokine, also showed a high production inhibitory activity of 45% or more, confirming that the fermented product of yeast extract has an inflammatory response inhibitory activity. The amount of nitric oxide in serum, another indicator of systemic inflammatory reaction caused by LPS, was also measured to show a high production inhibitory activity of 55% or more. The results are shown in Table 1.

Sample TNF -α ( pg / mL) IL- 1β Nitric oxide ( uM ) Vehicle 32.597 ± 1.209 12.174 + 0.896 0.722 + 0.041 Negative control 382.226 ± 15.467 128.462 + - 5.447 19.114 ± 1.005 Fermented fish 213.341 ± 16.822 71.229 + - 4.417 7.379 + 0.241

Claims (17)

(a) a step of culturing the herringbone in a liquid phase;
(b) carrying out a bioconversion fermentation process in which a mycelium of mycelium is inoculated in a liquid culture medium of a culture medium obtained in the step (a) and cultured and fermented; And
(c) producing a bioconversion product of the fermentation and enzyme treatment in which the antiallergic effect is improved through the bioconversion enzyme treatment process from the fermentation product produced by the bioconversion fermentation process in the step (b). A method for producing a fermented product with increased allergic potency.
The method according to claim 1,
Wherein the culturing medium of the allergen in the step (a) is prepared by treating the allergen powder obtained by pulverizing the perennial herb powder with a hydrolytic enzyme and sterilizing it to prepare a liquid allergen culture medium.
The method according to claim 1,
Wherein said enzymatic treatment is by enzymatic degradation of cellulolytic enzymes and amylases which are capable of decomposing cell wall components.
The method of claim 3,
Wherein said fibrinolytic enzyme is selected from the group consisting of cellulase, hemi-cellulase, pectinase and glucanase.
The method according to claim 1,
Wherein the mycelium of step (b) comprises mycelium of bacterium selected from the group consisting of a mushroom, a mushroom, a shiitake, a mushroom, a mushroom, a mushroom and a mushroom, ≪ / RTI >
The method according to claim 1,
Wherein the bioconversion product of step (c) inhibits the secretion of IgE in IgE-secreting B cells and inhibits the secretion of histamine in mast cells.
The method according to claim 1,
Wherein the bioconversion product of step (c) promotes the expression of TNF-a, IL-6, IL-10 and IFN-? In macrophages.
The method according to claim 1,
The bioconversion product of step (c) may be a method for producing a fermented product having increased anti-inflammatory activity, which decreases the concentration of TNF-α, IL-1β and nitric oxide in serum, which is an indicator of systemic inflammation in sepsis symptoms
A fermented product with increased antiallergic activity, which is fermented by inoculation with a mycelium of Mycobacterium tuberosus.
10. The method of claim 9,
Wherein the allergen is an allergic rhinitis, the fermentation product having increased antiallergic potency.
10. The method of claim 9,
The antiallergic effect reduces the production of IgE in allergic symptoms and inhibits the production of IL-2, IL-10, IL-12 and gamma-interferon in addition to inhibiting the production of IL-4, IL-5 and IL- Wherein the fermentation product has an increased antiallergic activity.
A fermented product for the treatment of allergy, comprising fermented product having increased antiallergic potency which is fermented by inoculating mycelia with bacterium mycelium.
13. The method of claim 12,
Wherein the allergic is allergic rhinitis.
A fermented product for the treatment of inflammation, which comprises a fermented product having increased antiallergic potency, which is fermented by culture inoculated with a mycelium of Mycobacterium sp.
15. The method of claim 14,
Wherein said inflammation treatment is a sepsis treatment.
A fermented food product for antiallergic use, comprising fermented product obtained by fermenting culture fermented with a mycelium of Mycobacterium sp.
A cosmetic composition for antiallergic use, comprising a fermented product having increased antiallergic potency obtained by inoculation with a mycelium of Mycobacterium sp.

Images